Eli Lilly (LLY) Ascends While Market Falls: Some Facts to Note
Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking is working on a weight-loss drug candidate that works in the same way as Eli Lilly's top-selling drug. The company released positive data recently, and the shares soared in the triple digits.
Eli Lilly CEO on Fighting Obesity, Developing New Drugs
Eli Lilly chairman and CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club...
Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Viking Therapeutics recently unveiled positive clinical trial results for its anti-obesity medication. The treatment is in phase 2 trials, but its results suggest it could rival other weight loss d...
Eli Lilly's campaign seeks to resolve weight-loss drug misconceptions
Eli Lilly is launching a campaign aimed at informing consumers about the seriousness of diabetes as a disease and the appropriate use of its weight-loss-related drugs.
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly shares have soared in the triple digits over the past year. Investors are excited about the company's prospects in the high-growth, weight-loss drug market.
Why Eli Lilly Stock Flopped on Friday
The pharmaceutical giant was informed that a regulatory decision on its Alzheimer's drug candidate has been delayed. The FDA would like to conduct more reviews with its advisors over the drug's per...
Eli Lilly's Alzheimer's Drug Release Delayed for FDA Investigation
Shares of Eli Lilly & Co. (LLY) were down more than 2% Friday after the pharmaceutical company announced that the Food and Drug Administration (FDA) wants more information about its experimental Al...
What Is Donanemab? Eli Lilly's Alzheimer's Drug Gets Delayed Decision From FDA
The FDA has delayed a decision on whether it will approve donanemab, Eli Lilly's closely watched new Alzheimer's drug, despite promising study results that showed it could significantly slow cognit...
Eli Lilly Stock Slips on FDA Approval Delay
Eli Lilly and Co (NYSE:LLY) stock is slipping today, after the U.S. Food & Drug Administration (FDA) delayed approving the drugmaker's Alzheimer's drug, donanemab, which was expected to be approved...
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
The FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's safety and efficacy.
Eli Lilly Says FDA Delays Decision on Alzheimer's Drug
The FDA plans to hold a special committee to discuss the Phase 3 trial results of donanemab.
Related Companies